Adverum Biotechnologies IncNASDAQ:ADVM
- LAST PRICE7.6900
- TODAY'S CHANGE (%)0.1500 (1.9894%)
- Bid / Lots7.6800/ 5
- Ask / Lots7.7000/ 2
- Open / Previous Close7.5300 / 7.5400
- Day Range
- 52 Week Range
- Volume66,091
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ADVM |
|---|---|---|
| 09:32 ET | 2882 | 7.26 |
| 09:33 ET | 212 | 7.53 |
| 09:35 ET | 730 | 7.4604 |
| 09:39 ET | 500 | 7.425 |
| 09:42 ET | 800 | 7.425 |
| 09:44 ET | 200 | 7.435 |
| 09:46 ET | 1700 | 7.57 |
| 09:48 ET | 704 | 7.56 |
| 09:50 ET | 200 | 7.57 |
| 09:51 ET | 500 | 7.6 |
| 09:53 ET | 400 | 7.625 |
| 09:55 ET | 600 | 7.64 |
| 09:57 ET | 500 | 7.61 |
| 10:00 ET | 426 | 7.64 |
| 10:02 ET | 636 | 7.6 |
| 10:04 ET | 200 | 7.59 |
| 10:06 ET | 100 | 7.59 |
| 10:08 ET | 100 | 7.59 |
| 10:13 ET | 1300 | 7.55 |
| 10:15 ET | 1500 | 7.575 |
| 10:18 ET | 100 | 7.56 |
| 10:20 ET | 300 | 7.56 |
| 10:24 ET | 300 | 7.56 |
| 10:27 ET | 324 | 7.53 |
| 10:31 ET | 100 | 7.555 |
| 10:33 ET | 258 | 7.542 |
| 10:36 ET | 1392 | 7.53 |
| 10:40 ET | 200 | 7.545 |
| 10:42 ET | 100 | 7.57 |
| 10:44 ET | 300 | 7.56 |
| 10:45 ET | 400 | 7.58 |
| 10:56 ET | 998 | 7.596 |
| 10:58 ET | 1998 | 7.5601 |
| 11:00 ET | 200 | 7.595 |
| 11:02 ET | 300 | 7.605 |
| 11:03 ET | 100 | 7.61 |
| 11:05 ET | 531 | 7.65 |
| 11:07 ET | 100 | 7.66 |
| 11:09 ET | 700 | 7.68 |
| 11:12 ET | 300 | 7.67 |
| 11:14 ET | 1030 | 7.66 |
| 11:20 ET | 288 | 7.64 |
| 11:23 ET | 100 | 7.665 |
| 11:25 ET | 400 | 7.67 |
| 11:30 ET | 3021 | 7.75 |
| 11:32 ET | 100 | 7.7325 |
| 11:38 ET | 120 | 7.7672 |
| 11:39 ET | 868 | 7.745 |
| 11:43 ET | 1375 | 7.67 |
| 11:45 ET | 600 | 7.67 |
| 11:48 ET | 247 | 7.67 |
| 11:52 ET | 300 | 7.67 |
| 11:56 ET | 400 | 7.67 |
| 12:01 ET | 142 | 7.61 |
| 12:08 ET | 100 | 7.615 |
| 12:10 ET | 757 | 7.6275 |
| 12:12 ET | 388 | 7.59 |
| 12:17 ET | 100 | 7.615 |
| 12:21 ET | 100 | 7.6 |
| 12:24 ET | 207 | 7.59 |
| 12:28 ET | 400 | 7.62 |
| 12:30 ET | 100 | 7.62 |
| 12:37 ET | 192 | 7.59 |
| 12:44 ET | 700 | 7.6 |
| 12:55 ET | 192 | 7.57 |
| 01:00 ET | 986 | 7.56 |
| 01:02 ET | 1100 | 7.57 |
| 01:04 ET | 100 | 7.5577 |
| 01:08 ET | 247 | 7.55 |
| 01:11 ET | 100 | 7.55 |
| 01:15 ET | 496 | 7.56 |
| 01:18 ET | 400 | 7.56 |
| 01:27 ET | 132 | 7.57 |
| 01:29 ET | 236 | 7.55 |
| 01:38 ET | 191 | 7.56 |
| 01:40 ET | 500 | 7.5603 |
| 01:44 ET | 600 | 7.58 |
| 01:45 ET | 100 | 7.6 |
| 01:54 ET | 1510 | 7.626 |
| 02:00 ET | 191 | 7.6 |
| 02:03 ET | 1000 | 7.65 |
| 02:20 ET | 100 | 7.64 |
| 02:21 ET | 739 | 7.659 |
| 02:30 ET | 300 | 7.64 |
| 02:36 ET | 101 | 7.65 |
| 02:38 ET | 200 | 7.67 |
| 02:39 ET | 232 | 7.65 |
| 02:43 ET | 400 | 7.685 |
| 02:50 ET | 200 | 7.705 |
| 02:56 ET | 324 | 7.69 |
Today
Yesterday
Oct 16, 2024
Press Release: Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program, from 8:00AM ET on Wednesday Oct 16, 2024 by Dow Jones
8:00AM ET on Wednesday Oct 16, 2024 by Dow JonesAdverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program, from 8:00AM ET on Wednesday Oct 16, 2024 by Dow Jones
8:00AM ET on Wednesday Oct 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Adverum Biotechnologies Inc | 156.8M | -1.0x | --- |
Checkpoint Therapeutics Inc | 157.1M | -2.1x | --- |
Verastem Inc | 157.0M | -1.1x | --- |
Galectin Therapeutics Inc | 157.3M | -3.3x | --- |
CAMP4 Therapeutics Corp | 160.3M | -3.7x | --- |
Vigil Neuroscience Inc | 153.4M | -1.8x | --- |
Company Information
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.
Contact Information
- Headquarters
- 100 Cardinal WayREDWOOD CITY, CA, United States 94063
- Phone
- 650-649-1004
- Fax
- 650-329-8151
Executives
- Independent Chairman of the Board
- Patrick Machado
- President, Chief Executive Officer, Director
- Laurent Fischer
- Chief Financial Officer
- Linda Rubinstein
- Chief Operating Officer
- Kishor Soparkar
- Chief Medical Officer
- Rabia Ozden
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $156.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 20.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.94 |
EPS | $-7.99 |
Book Value | $8.23 |
P/E Ratio | -1.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
